Leptomeningeal Metastasis Clinical Trials

21 recruiting

Leptomeningeal Metastasis Trials at a Glance

26 actively recruiting trials for leptomeningeal metastasis are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in Huizhou, Zhengzhou, and Shanghai. Lead sponsors running leptomeningeal metastasis studies include Guangzhou Medical University, Henan Cancer Hospital, and The First Affiliated Hospital with Nanjing Medical University.

Browse leptomeningeal metastasis trials by phase

Treatments under study

About Leptomeningeal Metastasis Clinical Trials

Looking for clinical trials for Leptomeningeal Metastasis? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Leptomeningeal Metastasis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Leptomeningeal Metastasis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting
Phase 1Phase 2

Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer

Leptomeningeal Metastasis From Lung Cancer
Henan Cancer Hospital14 enrolled1 locationNCT07559097
Recruiting
Not Applicable

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

Leptomeningeal MetastasisLung Neoplasms, Non-Small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University30 enrolled1 locationNCT07398599
Recruiting
Not Applicable

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Leptomeningeal MetastasisNSCLC (Advanced Non-small Cell Lung Cancer)EGFR Activating Mutation+1 more
Guangzhou University of Traditional Chinese Medicine42 enrolled1 locationNCT07348965
Recruiting
Phase 1

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Leptomeningeal MetastasisLung Cancer (NSCLC)
Shanghai Chest Hospital19 enrolled1 locationNCT06663306
Recruiting
Phase 2

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Metastatic CancerLeptomeningeal MetastasisBrain Cancer+2 more
Memorial Sloan Kettering Cancer Center30 enrolled1 locationNCT06058988
Recruiting
Phase 1Phase 2

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

HER2-positive Breast CancerLeptomeningeal DiseaseLeptomeningeal Metastasis
H. Lee Moffitt Cancer Center and Research Institute39 enrolled2 locationsNCT04588545
Recruiting
Phase 2

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Leptomeningeal Metastasis
Guangzhou Medical University36 enrolled1 locationNCT06296745
Recruiting
Phase 2

A Prospective Single Arm Phase II Exploratory Study on the Combination of Whole Brain Radiotherapy, Thiotepa Intrathecal Injection and Systemic Treatment of Primary Diseases in the Treatment of Solid Tumor Leptomeningeal Metastasis

Solid Tumor Leptomeningeal Metastasis
Second Affiliated Hospital, School of Medicine, Zhejiang University58 enrolled1 locationNCT06376292
Recruiting

Study in Patients With Breast Cancer Leptomeningeal Metastasis

Leptomeningeal Metastasis of Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins30 enrolled2 locationsNCT06638294
Recruiting
Phase 2

Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis

Leptomeningeal Metastasis of HER2-positive Breast Cancer
The First Affiliated Hospital with Nanjing Medical University26 enrolled1 locationNCT07263425
Recruiting
Phase 4

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

HER2-negative Breast CancerLeptomeningeal Metastasis
Fudan University37 enrolled1 locationNCT06230055
Recruiting
Phase 2

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

HER2-positive Metastatic Breast CancerLeptomeningeal DiseaseLeptomeningeal Metastasis
UNICANCER30 enrolled11 locationsNCT05800275
Recruiting
Not Applicable

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Leptomeningeal Metastasis
Guangzhou Medical University100 enrolled1 locationNCT06304441
Recruiting
Phase 1

Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Leptomeningeal Metastasis
Plus Therapeutics24 enrolled1 locationNCT07098806
Recruiting
Phase 4

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

NSCLCLeptomeningeal MetastasisTyrosine Kinase Inhibitor+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology40 enrolled1 locationNCT07092202
Recruiting
Phase 1Phase 2

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

Leptomeningeal MetastasisIntrathecal Drug Delivery
Guangzhou Medical University34 enrolled1 locationNCT06809517
Recruiting
Phase 1Phase 2

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

Leptomeningeal Metastasis
Guangzhou Medical University36 enrolled1 locationNCT06762080
Recruiting
Phase 1Phase 2

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Solid TumorsLeptomeningeal MetastasisCTLA4+2 more
Guangzhou Medical University34 enrolled2 locationsNCT06809530
Recruiting
Not Applicable

Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis

Leptomeningeal Metastasis
University of Aarhus50 enrolled2 locationsNCT05746754
Recruiting
Phase 2

A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases

Leptomeningeal Metastasis
Shanghai Cancer Hospital, China97 enrolled1 locationNCT06901817